Objectives: Assessment outcome of DOTS (Directly observed therapy short course) program in Al-Sader City
Sector that was established by the WHO.
Methodology: Three cohorts groups of patients attending Baghdad TB institute and TB center in Al-Sader city
were followed retrospectively. The 1st cohort included (314) patients registered in year (2003), the 2nd cohort
included (327) patients registered in year (2004), the 3rd cohort included (321) patients registered in year
(2005). The collected data were analyzed for case detection, treatment outcomes, retreatment outcomes,
treatment success, and retreatment success in regard to time, age and sex.
Results: The following rates were extracted for the three cohort: Case detection rate within 1st, 2nd, and 3rd
cohort were (73.36%, 64.24%, and 71.49% respectively).Treatment outcomes (cured, completed treatment,
defaulters, treatment failure, died and transfer out) of new smear positive patients within the 1st, 2nd and 3rd
were (71.7%, 12.7%, 10.2%, 3.5%, 1%, 1%), (64.8%, 19.9%, 0.9%, 7%, 0.6%, 6.7%) and (61.4%, 24%, 3.1%, 5.9%,
0.6%, 5% respectively).Retreatment outcomes (cured, completed treatment, defaulters, treatment failure, died
and transfer out) within 1st, 2nd and 3rd cohort were (55.6%, 7.9%, 6.6%, 15.2%, 4%, 10.6%), (44.9%, 7.7%,
2.6%, 21.8%, 4.5%, 18.6%) and (41.8%, 14.6%, 11.4%, 19.6%, 1.9%, 10.8% respectively. Treatment success rate
within the 1st, 2nd and 3rd cohort were (84.39%, 84.7%, and 85.35%) respectively. Retreatment success rate
within the 1st, 2nd and 3rd cohort was (63.57%, 52.56%, and 56.32%) respectively.
Recommendation :Increase case detection rate through increase health awareness to the community about
the mode of transmission and risk of TB disease, Increase the training of health team so that they can follow up
of patients at home, Increase follows up of defaulters to be able to deal with them and a study for relapses
cases is recommended
Despite the G protein-coupled receptors (GPCRs) being the largest family of signalling proteins at the surface of cells, their potential to be targeted in cancer therapy is still under-utilised. This review highlights the contribution of these receptors to the process of oncogenesis and points to some likely challenges that might be encountered in targeting them. GPCR-signalling pathways are often complex and can be tissue-specific. Cancer cells hijack these communication networks to their proliferative advantage. The role of selected GPCRs in the different hallmarks of cancer is examined to highlight the complexity of targeting these receptors for therapeutic benefit. Our
... Show More
KE Sharquie, AA Noaimi, Glob Dermatol, 2014 - Cited by 6
WKAJ Khalifa E. Sharqui1,*, Adil A. Noaimi2, Ali R. Auda3, American Journal of Dermatology and Venereology, 2014 - Cited by 1
(6)
(1)
(4)
S Khalifa E, N Adil A, AS Mazin M…, 2008
(42)
KE Sharquie, AA Noaimi, MM Al-Salih, Saudi Medical Journal, 2008 - Cited by 56
Hypothyroidism has been associated with disorders of glucose and insulin metabolism..The present study was designed to evaluate the possible change in some hormones (free testosterone, estradiol, prolactin, insulin), glucose and homeostasis model assessment of insulin resistance (HOMA-IR) in women with primary hypothyroidism under thyroid hormone replacement therapy .This cross-sectional study was carried on 62 hypothyroid patients׳ women and 22 healthy women as control group at the specialized center for endocrinology and diabetes, AL-Rasafa Directorate of Health Baghdad, with age range(15-60 years), diagnosed as having primary hypothyroidism on thyroxine replacement therapy with duration not less than four months.
... Show More
Checkpoint inhibitors are a type of immune therapy used to treat different types of cancers. These drugs block different checkpoint proteins, for example, CTLA-4, PD-1, and PD-L1 inhibitors.
They block proteins that stop the immune system from attacking the cancer cells. Checkpoints are also described as a type of monoclonal antibody that antagonizes binding between B7 to CTLA-4 and PD-L1 to PD-1.
Immune checkpoint inhibitors are used to treat BARCA mutated triple-negative breast cancer (TNBCS) in patients who do not respond to chemotherapy, and also in the treatment of highly mutated and solid tumors such as brain tumors, liver, and pancreatic cancers.
Immune checkpoint inhibitors exhibit an effect on solid tumo
... Show More
(1)